Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a globally recognized leader in medical and recreational cannabis production, operating advanced facilities that meet stringent international standards. This page serves as the definitive source for verified news and official announcements impacting ACB's market position and strategic initiatives.
Access real-time updates including quarterly earnings, regulatory compliance milestones, product launches, and partnership agreements. Investors will find essential details on operational expansions, while analysts gain insights into ACB's research-driven approach to cannabis cultivation and global distribution strategies.
Key coverage areas span clinical trial developments, international market entries, sustainability initiatives, and innovations in cannabis-derived health products. All content is curated to meet investor-grade reliability standards, sourced directly from company filings and accredited industry publications.
Bookmark this page for streamlined access to ACB's evolving narrative in the global cannabis sector. Combine our updates with Stock Titan's financial tools to monitor market reactions and long-term trends.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) held its Annual General and Special Meeting on August 9, 2024, with 27.23% of issued and outstanding shares represented. All proposed matters were approved by shareholders, including the election of directors, appointment of Ernst & Young LLP as auditors, amendments to various compensation plans, renewal of the Shareholder Rights Plan, and a non-binding advisory resolution on executive compensation.
Notable voting results for director elections include Miguel Martin with 93.29% votes FOR, Chitwant Kohli with 92.37% votes FOR, and Norma Beauchamp with 89.47% votes FOR. The lowest approval was for Ron Funk, receiving 79.26% votes FOR.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced its Q1 fiscal 2025 results, highlighting positive free cash flow of $6.5 million and a 12% year-over-year increase in total quarterly net revenue to $83.4 million. The company achieved record net revenue of $47.2 million in global medical cannabis and generated Adjusted EBITDA of $4.9 million, an 87% YoY increase. Aurora ended the quarter with a debt-free cannabis business and a cash position of ~$182 million. The company's performance was driven by strong growth in the global medical cannabis segment and a record contribution from its Bevo plant propagation business. Aurora's CEO, Miguel Martin, emphasized the company's commitment to operational excellence and strategic growth, positioning it well for sustained positive momentum.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc. have announced a commercial collaboration to launch a new CBD lozenge on Aurora's Canadian medical cannabis patient platform. The product, developed by Cogent International (a Vectura Fertin Pharma subsidiary), will be available to Aurora's patient base, providing valuable feedback and real-world data. This collaboration may lead to the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.
The initial agreement has a 24-month term, with the first CBD lozenge expected to launch later in 2024. Cogent will manufacture, package, and label the products for Aurora to distribute through its direct-to-patient e-commerce sales channel. This partnership aims to advance medical cannabis options in Canada while requiring minimal additional capital investment from Aurora.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) is reminding shareholders to vote for its 2024 Annual General and Special Meeting, scheduled for August 9, 2024 at 1:00 p.m. Eastern Time. The proxy voting deadline is August 7, 2024 at 1:00 p.m. Eastern Time. The Board of Directors recommends voting FOR all director nominees and proposed resolutions.
Shareholders can attend the meeting via live webcast and are encouraged to review meeting materials available on Aurora's website and SEDAR+. For voting assistance, shareholders can contact Laurel Hill Advisory Group, Aurora's proxy solicitation agent. The company emphasizes that every vote is important, regardless of the number of shares owned.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has announced its upcoming first quarter 2025 investor conference call. The call is scheduled for Wednesday, August 7, 2024, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time). Aurora will release its financial results for Q1 2025 before the markets open on the same day.
The conference call will be hosted by CEO Miguel Martin and CFO Simona King, who will present the results and conduct a question and answer session. Investors can access the webcast through the company's website under the 'Investor Info' section.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has been granted expanded cultivation and unique research licenses by Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The licenses allow Aurora to continue domestic cultivation, add an approved additional product, and conduct R&D on up to seven novel cultivars at its EU GMP facility in Leuna. This expansion builds on Aurora's two-year history of cultivating approximately 1,000 kg of medical cannabis flower annually in Germany. The company views these licenses as recognition of its leadership in the region and commitment to high-quality cannabis production. Aurora anticipates that Germany's regulatory reforms will have a broader effect on the acceptance of medical cannabis across Europe.
Aurora Cannabis announces the availability of its management information circular for its upcoming annual general and special meeting of shareholders. The meeting will be held virtually on August 9, 2024, at 1:00 p.m. (Eastern time) / 11:00 a.m. (Mountain Time). Shareholders can access the circular on the company's website and SEDAR+. At the meeting, shareholders will vote on critical issues, including director nominees and meeting resolutions. Aurora emphasizes its recent financial stability and aims for positive free cash flow by the end of 2024. The company encourages shareholders to vote by August 7, 2024, and reach out to Laurel Hill Advisory Group for assistance.
Aurora Cannabis (NASDAQ: ACB) announced its FY2024 results, highlighting a record annual adjusted EBITDA of $12.8 million and a 21% increase in total net revenue compared to the previous fiscal year. In Q4 2024, the company achieved its sixth consecutive quarter of positive adjusted EBITDA, with total net revenue up 5% YoY to $67.4 million, driven by a 20% YoY growth in global medical cannabis revenue to $45.6 million. Aurora finished the fiscal year with approximately $180 million in cash and no cannabis-related debt. The company reaffirms its goal of achieving positive free cash flow by the end of 2024.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, announced that it will host a conference call to discuss its fourth quarter and fiscal year 2024 results. The call is scheduled for Thursday, June 20, 2024, at 8:00 a.m. Eastern Time. The financial results for the quarter will be released before the market opens on the same day. Miguel Martin, CEO, and Simona King, CFO, will lead the call and a subsequent Q&A session. The webcast link can be accessed on the company's investor information page.
Aurora Cannabis, a leading medical cannabis company, has announced the launch of its premium 1.2g resin cartridges in Australia in partnership with MedReleaf Australia. These new products are now available for doctors to prescribe and are manufactured in Aurora's EU-GMP and TGA-GMP certified facilities.
The resin cartridges come under the Aurora and IndiMed brands, offering high-quality, full-spectrum options like Sourdough and Electric Honeydew. The products are designed to ensure exceptional flavor, potency, safety, and ease of use.
This move marks a significant expansion for Aurora, aiming to enhance patient access to premium cannabis in the Australian market.
FAQ
What is the current stock price of Aurora Cannabis (ACB)?
What is the market cap of Aurora Cannabis (ACB)?
